A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors
- First Online:
- 91 Downloads
Chemotherapy regimens including gemcitabine in combination with microtubule inhibitors such as docetaxel and paclitaxel have wide clinical application. Patupilone is a novel tubulin-polymerizing agent with activity against paclitaxel-resistant cell lines. We conducted a phase I trial to assess the maximum tolerated dose, dose limiting toxicity (DLT) and antitumor activity of gemcitabine and patupilone.
Patients with refractory solid tumors enrolled in cohorts of three. Cohorts received fixed doses of gemcitabine (1,000 or 750 mg/m2) along with escalating doses of patupilone (1.5–3 mg/m2) on days 1 and 8 of a 21-day cycle.
Twenty-seven patients received a total of 99 courses of treatment on study. Hematologic toxicity in the first cohort required a modification of the protocol to decrease the gemcitabine dose. Subsequent patients received gemcitabine 750 mg/m2 and escalating doses of patupilone from 1.5 to 3 mg/m2. DLTs were grade 3 asthenia and grade 3 dehydration. There was also one treatment-related death due to neutropenic infection. Other clinically significant toxicities were persistent asthenia and persistent nausea. Four patients, one each with pancreatic cancer, esophageal carcinoma, cholangiocarcinoma and gallbladder carcinoma, experienced a partial response.
The dose-limiting toxicities of gemcitabine and patupilone were asthenia and dehydration. Dose reductions also occurred due to persistent fatigue that was not dose-limiting. However, patients with advanced malignancies were able to tolerate gemcitabine and patupilone at doses that resulted in clinical benefit. The recommended phase II dose for this schedule is gemcitabine 750 mg/m2 and patupilone 1.5 mg/m2 on days 1 and 8 of a 21-day cycle.
KeywordsGemcitabine Patupilone Chemotherapy Phase I
- 7.Wenger F, Duboc L, Tinetto W, O’Reilly T. CGP 47906 (epothilone B) is active in models of ovarian and glioma tumors. Release Ready Report PKF-98-01821. July 31, 1998Google Scholar
- 8.Wartmann M, Woods-Cook K, Mett H. In vitro cytotoxicity profile of the antimicrotubule agent EPO906 (CCP 47906, epothilone B) in comparison with paclitaxel. Release Ready Report PKF-98-03317. Nov. 24, 1998Google Scholar
- 9.Calvert PM, O’Neill V, Twelves C, Azzabi A, Hughes A, Bale C, Robinson A, Machan M, Dimitrijevic S, Moss D, Rothermel J, Cohen P, Chen T, Man A, Calvert AH (2001) A phase I clinical and pharmacokinetic study of EPO906 (epothilone B), given every three weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 20:108, (abstr 429)Google Scholar
- 11.Hussain A, Dipaola RS, Baron AD, Higano CS, Tchekmediyan NS, Miller JA, Rothermel JD (2004) A phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 22:397, (abstr 4563)Google Scholar
- 13.Thompson JA, Swerdloff J, Escudier B, Dutcher JP, Bukowski RM, Vaishampayan U, Hussein A, Negrier S, Rothermel J (2004) Phase II trial evaluating the safety and efficacy of EPO906 in patients with advanced renal cancer. Proc Am Soc Clin Oncol 22:405, (abstr 1628)Google Scholar
- 24.Kosmoas C, Tsavairs N, Vadiaka M, Stavroyianni N, Koutras A, Malamos N, Onyenadum A, Rokana S, Polyzos A, Kalofonos HP (2001) Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Cancer 92:2902–2910CrossRefGoogle Scholar
- 25.Hainsworht JD, Burris HA 3rd, Billings FT 3rd, Bradof JE, Baker M, Greco FA (2001) Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: phase II trials of the Minnie pearl cancer research network. Cancer 92:2391–2398CrossRefGoogle Scholar
- 27.Pouessel D, Culine S, BEcht C, Romieu G, Gabbro M, Ychou M, Cupissol D, Pinguet F (2004) Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res 23:2801–2804Google Scholar
- 32.Shepard RC, Levy DE, Berlin JD, Stuart K, Harris JE, Aviles V, Thomas JP, Benson AB 3rd (2004) Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group. Oncology 66(4):303–309PubMedCrossRefGoogle Scholar
- 35.Poplin E, Moore M, O’Dwyer P, Clarke S, Hill M, Sessa C, Rothermel J, Jull R, Miller J, Rosen L (2004) Safety and efficacy of EPO906 in patients with advanced colorectal cancer: a review of 2 phase II trials. Proc Am Soc Clin Oncol 22:283, (abstr 1135)Google Scholar
- 36.Smit WM, Sufliarsky J, Spanik S, Wagnerová M, Kaye S, Oza AM, Gore M, Williams K, Jorhi A, Ten Bokkel Huinink WW (2005) Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer. Proc Am Soc Clin Oncol 23:468, (abstr 5056)Google Scholar
- 37.Melichar B, Tabernor J, Casodo E, Bridgewater J, Hamm J, Sklenar I, Holland J, Cheung W, Zaknoen S, Johri A (2005) Phase I dose optimization trial of patupilone in previously treated patients with advanced colon cancer. Proc Am Soc Clin Oncol 23:292, (abstr 3688)Google Scholar
- 38.Rinehart JJ, Rothermel JD, Anderson J, Lorusso P (2004) Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus gemcitabine in patients with advanced cancer. Proc Am Soc Clin Oncol 22:14S, (abstr 3100)Google Scholar